Overview

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This protocol is intended to compare the effects of both a solid (tablet) and liquid oral dosage form of LX4211 in subjects with type 2 diabetes mellitus.

Phase:

Phase 1

Details

Lead Sponsor:

Lexicon Pharmaceuticals

Treatments:

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol